Company: HYEX
Filing Date: 2025-04-22
Form Type: 10-K/A
Source: 0001096906-25-000553
Chunk: 44

Company: HEALTHY EXTRACTS INC.
Filing Date: 2025-04-22
Form: 10-K/A
Chunk 44
---
 or the industry in which we operate, including the nutraceutical industry which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis; ·changes in market valuations of similar companies; ·market reaction to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings of our existing stockholders; ·additions or departures of key personnel; ·actions by institutional or significant stockholders; ·short interest in our Common Stock or our other securities and the market response to such short interest; ·the dramatic increase in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative investing; ·speculation in the press or investment community about our company or industries in which we operate; ·strategic actions by us or our competitors, such as acquisitions or other investments; ·legislative, administrative, regulatory or other actions affecting our business, our industry, including positions taken by the FDA; ·investigations, proceedings, or litigation that involve or affect us; ·the occurrence of any of the other risk factors included in this annual report; and ·general market and economic conditions. A significant portion of our total outstanding shares of Common Stock are restricted from immediate resale but may be sold into the market in the near future, which could cause the market price of our Common Stock to drop significantly, even if our business is performing well. Sales of a substantial number of shares of our Common Stock in the public market could occur at any time, subject to certain restrictions described below. All of the Shares will be freely tradable without restrictions or further registration under the Securities Act, except for any shares held by our affiliates as defined in Rule 144 under the Securities Act (“Rule 144”). These sales, or the perception in the market that holders of a large number of shares of our Common Stock intend to sell shares, could reduce the market price of our Common Stock. We have outstanding 2,989,406 shares of Common Stock, 648,890 of which 35 may be resold in the public market immediately without restriction, and the rest of which may be sold pursuant to Rule 144. Also, we intend to register all shares of Common Stock that we may issue under our equity compensation plan on a registration statement on Form S-8. Upon such registration, such shares can be freely sold in the public market upon issuance, subject to the terms of applicable award agreements, volume limitations applicable to affiliates and lock-up agreements.